Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study

Background: To compare adverse event (AE) profiles between patients with prostate cancer receiving triplet therapy (docetaxel, androgen receptor signaling inhibitors [ARSIs], and androgen deprivation therapy [ADT]) and those receiving docetaxel-based therapy (docetaxel and ADT). Additionally, we sou...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Fumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, Hidetsugu Takahashi, Masaki Hashimoto, Shuhei Hara, Wataru Fukuokaya, Yu Imai, Kosuke Iwatani, Taro Igarashi, Mahito Atsuta, Kojiro Tashiro, Masaya Murakami, Shunsuke Tsuzuki, Brendan A. Yanada, Toshihiro Yamamoto, Kenichi Hata, Hiroki Yamada, Jun Miki, Takahiro Kimura
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Elsevier 2025-03-01
Reeks:	Prostate International
Onderwerpen:	Adverse event Docetaxel mCSPC Neutropenia Triplet therapy
Online toegang:	http://www.sciencedirect.com/science/article/pii/S2287888224000850
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!